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Abstract
Introduction—Tumor genotyping using single gene assays (SGAs) is standard practice in 
advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next 
generation sequencing (NGS) into day-to-day clinical practice altered therapeutic decision-
making.
Methods—Clinicopathologic data, tumor genotype, and clinical decisions were retrospectively 
compiled over 6 months following introduction of NGS assay use at our institution in 82 patient-
tumor samples (7 by primary NGS, 22 by sequential SGAs followed by NGS, and 53 by SGAs).
Results—SGAs identified abnormalities in 34 samples, and all patients with advanced EGFR-
mutated or ALK-rearranged tumors received approved tyrosine kinase inhibitors (TKIs) or were 
consented for clinical trials. NGS was more commonly requested for EGFR, ALK, and KRAS-
negative tumors (p<0.0001). NGS was successful in 24/29 (82.7%) tumors. Of 17 
adenocarcinomas (ACs), 11 (7 from patients with ≤15 pack-years of smoking) had abnormalities 
in a known driver oncogene. This led to a change in decision-making in 8 patients, trial 
consideration in 6, and off-label TKI use in 2. Of 7 squamous cell (SC) carcinomas, 1 had a driver 
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aberration (FGFR1); 6 had other genomic events (all with TP53 mutations). In no cases were 
clinical decisions altered (p=0.0538 when compared to ACs).
Conclusions—Targeted NGS can identify a significant number of therapeutically-relevant 
driver events in lung ACs; particularly in never or light smokers. For SC lung cancers, NGS is less 
likely to alter current practice. Further research into the cost effectiveness and optimal use of NGS 
and improved provider training in genomic oncology are warranted.
Keywords
Non-small-cell lung cancer; next generation sequencing; genotype; EGFR; ALK; driver oncogene; 
MET; ROS1; MET; adenocarcinoma; squamous cell carcinomas
1. INTRODUCTION
The management of advanced non-small-cell lung cancer (NSCLC) is increasingly directed 
by knowledge of tumor genotype. Expert groups like the College of American Pathologists 
(CAP), the International Association for the Study of Lung Cancer (IASLC), the Association 
for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) 
now endorse routine testing for epidermal growth factor receptor (EGFR) mutations or 
anaplastic lymphoma kinase (ALK) rearrangements using rapid single gene assays (SGAs) 
(1-3). Knowledge of these predictive biomarkers has permitted selective application of 
tyrosine kinase inhibitors (TKIs) (1-3), with EGFR and ALK TKIs having gained approval 
from the U.S. Food and Drug Administration (FDA) on the basis of these genomic features 
(4-9).
The genetic landscape of NSCLC is complex. Oncogenic and/or therapeutically-relevant 
genomic aberrations include: mutations, amplifications, deletions, and rearrangements/
fusions. It is now well established that a significant proportion of lung adenocarcinomas 
(ACs) harbor mutations in driver oncogenes that can augment “sustained proliferative 
signaling” - a hallmark feature of tumorigenesis. These include mutations in: v-ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS), Raf murine sarcoma viral oncogene 
homolog B1 (BRAF), V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), 
rearranged during transfection (RET), c-ros oncogene 1 (ROS1), and neurotrophic tyrosine 
kinase receptor type 1 (NTRK1), among others (10). Squamous cell (SC) lung cancers may 
instead harbor genomic changes involving: fibroblast growth factor receptor (FGFR) 
1/2/3/4, phosphatidylinositol-3-kinase catalytic subunit alpha1 (PIK3CA), and discoidin 
domain-containing receptor 2 (DDR2), among others (10, 11).
Technological advances have led to the introduction of next generation sequencing (NGS) 
platforms into the thoracic oncology clinic (10). As opposed to SGAs, NGS permits massive 
parallel sequencing that affords maximal tumor genomic assessment while using precious 
tumor samples sparingly (12). These NGS assays offered by Clinical Laboratory 
Improvement Amendments (CLIA)-certified commercial or academic vendors are usually 
only feasible when based on a targeted panel of genes (i.e. targeted NGS) that select for the 
most readily targetable alterations. Many of these NGS assays, especially whole genome and 
whole exome, require substantial nucleic acid input (250ng-1ug), though some have been 
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optimized to allow results from lower concentrations of deoxyribonucleic acid (DNA) and 
more recently ribonucleic acid (RNA) from formalin-fixed paraffin-embedded (FFPE) 
specimens or cytology specimens (12-14).
The feasibility and applicability of NGS in day-to-day clinical practice—as opposed to use 
in research settings alone—has not been well vetted in the literature to date. We therefore 
evaluated how the introduction of NGS assays into daily practice altered therapeutic 
decision-making for a cohort of NSCLCs treated by a multidisciplinary Thoracic Oncology 
team at this National Cancer Institute (NCI)-affiliated cancer center. In this cohort, NGS was 
applied as part of routine practice and not in parallel with other academic/commercial 
efforts, such as assay development or clinical trial screening.
2. METHODS
2.1 Cohort selection and data collection
Patients seen at Beth Israel Deaconess Medical Center (BIDMC, a member of the Dana-
Farber/Harvard Cancer Center) with a diagnosis of NSCLC and whose tumors were 
submitted for either SGA or NGS were identified through an ongoing Institutional Review 
Board-approved study (15, 16). Patient inclusion was restricted from May 1st to October 
31st, 2014 (the 6-month interval since introduction of NGS in clinical NSCLC specimens). 
Clinical, pathologic, radiographic, and tumor genotyping parameters were collected by 
retrospective chart extraction and managed using REDCap electronic data capture tools 
hosted at BIDMC. A review of clinical documentation, clinical trial screening/consent, and 
anti-cancer therapies administered allowed for determination of clinical decision-making.
2.2 Tumor genotyping
Following routine pathologic diagnosis of NSCLC, tumor material (from surgical 
specimens, core needle biopsies or cell aspirates/concentrates) in FFPE tissue blocks was 
submitted for genomic analysis. SGAs (EGFR exon 18-21 mutation analysis, KRAS codon 
12 and 13 mutation analysis, ALK fluorescence in situ hybridization [FISH], ROS1 FISH) 
and NGS were performed as previously described (13-17). Three different NGS assays were 
used. The first two were performed by an academic medical center (Massachusetts General 
Hospital; Boston, MA) using an anchored multiplex polymerase chain reaction (AMP) assay 
that employs a targeted sequencing strategy (13). The first AMP assay (SNaPshot-NGS-V1) 
evaluates single nucleotide variants (SNV) and insertions/deletions (indels) in genomic 
DNA using NGS targeting 39 putative oncogenes and tumor suppressor genes (13); this 
assay was used in 22 of the study cases. The second AMP assay (ALK, RET, ROS1 NGS 
Gene Fusion Assay) evaluates fusion transcript detection for ALK, ROS1 and RET using 
genomic RNA (13); this assay was used in 6 of the study cases. The third NGS assay 
(FoundationOne, Foundation Medicine; Cambridge, MA) interrogates 315 genes as well as 
introns of 28 genes involved in rearrangements using massively parallel DNA sequencing to 
characterize base substitutions, short indels, copy number alterations, and selected fusions 
(14); this assay was used in 2 of the study cases. A CLIA-certified single gene FGFR1 FISH 
test (Massachusetts General Hospital; Boston, MA) to evaluate copy number of FGFR1 (17) 
was used in addition to NGS in SC carcinomas; this assay was used in 5 of the study cases.
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2.3 Statistical methods
Fisher’s exact test was used to compare categorical variables. All p-values reported were 
two-sided.
3. RESULTS
3.1 Patient and tumor characteristics
Table 1 illustrates baseline patient and tumor characteristics. The cohort comprised 82 
patients, most of whom had stage IV/recurrent disease (72.0%) and AC histology (90.2%).
3.2 SGAs for EGFR/ALK/KRAS/ROS1 and clinical decisions
Figure 1 depicts the clinical use and outcomes of genomic analyses in the 82 patient-tumor 
samples. SGAs were ordered in 75 tumors. Analyses for abnormalities in EGFR, ALK, 
KRAS, and ROS1 were successful in: 94.6% (71/75), 96% (72/75), 94.4% (68/72), and 
79.7% (55/69), respectively. The increased failure rate of ROS1 testing is noted, raising the 
possibility of technical issues with the FISH test (rather than inherent lack of tumor 
material). Of successfully genotyped tumors, abnormalities in EGFR, ALK, KRAS, and 
ROS1 were found in: 14.0% (10/71), 4.1% (3/72), 30.8% (21/68), and 0% (0/55), 
respectively. Abnormalities in EGFR, KRAS, and ALK were mutually exclusive—except in 
one case with a concomitant EGFR exon 19 deletion and positive ALK FISH identified on 
the same sample.
A total of 10 patients with tumors harboring EGFR mutations were identified. Of these, 8 
with metastatic AC received an FDA-approved EGFR TKI (erlotinib), with 3 of the 8 
consenting for a clinical trial of erlotinib (www.clinicaltrials.gov: NCT00997334). One 
patient with stage III disease consented for a clinical trial of adjuvant afatinib 
(NCT01746251). One patient with stage III disease received concurrent chemoradiation, as 
per evidence-based guidelines.
All 3 patients with ALK-rearranged ACs received an FDA-approved ALK TKI: one received 
crizotinib, and 2 were consented for a clinical trial evaluating crizotinib versus alectinib 
(NCT02075840).
The 21 patients with KRAS-mutated ACs received standard therapies as per expert 
guidelines (3). Of the 16 patients with stage IV disease, 2 were eligible for and were offered 
a clinical trial (NCT01933932) following progression on standard platinum-doublet therapy.
35 patients had tumors that were negative for abnormalities in EGFR, ALK, and KRAS. None 
of these patients were offered off-label TKIs, but 3 of these patients consented for clinical 
trials using cytotoxic chemotherapy as a backbone.
3.3 Use of NGS assays and clinical decisions
NGS assays were ordered in 29 tumors, corresponding to 35.3% of the original cohort. 22 
NGS requests (21 ACs, 1 SC carcinoma) were made for tumors that had previously 
undergone first-pass SGAs. For the remaining 7 NGS requests (1 AC, 6 SC carcinomas), 
NGS was the lone genomic test requested (Figure 1B). Of the 22 NGS assays that were 
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requested following initial SGAs, nearly all (21/22, 95.4%) came from tumors that had 
previously tested negative for abnormalities in EGFR, ALK, and KRAS. Conversely, the 
majority (21/35, 60%) of tumors testing negative for EGFR, ALK, and KRAS on initial SGAs 
were subsequently sent for NGS (Figure 1A). There were no observed discrepancies 
between NGS and SGA results. Of the 29 total tumors submitted for NGS, 24 (82.7%) had 
successful results. The failure rate was higher if the sample had been previously submitted 
for SGAs (5/22, 22.7%), as compared to a failure rate of 0% (0/7) when NGS was the initial 
genomic test (p=0.2965).
Of the 24 successful samples undergoing NGS, most (17/24, 70.8%) were of AC histology, 
the majority of which (11/17, 64.7%) harbored a well-established driver oncogene: 1 EGFR-
mutated, 2 ERBB2-mutated, 1 ROS1-rearranged, 1 RET-rearranged, 2 KRAS-mutated, 1 
MET-amplified tumor, 2 MET-exon 14 splicing mutated, and 1 MAP2K1-mutated tumor; 
concurrent TP53 mutations were seen in 40% of cases. Of the 6 tumors without an 
identifiable principal oncogene mutation, TP53 mutations were most common (66.6%). 
Details of individual tumor genotyping results and clinical decisions are listed in Table 2.
Clinical decisions were impacted by NGS results in 8/17 (47.0%) ACs. A total of 6 patients 
were considered for clinical trials available at our institution on the basis of findings from 
NGS: 4 consented for a clinical trial of an oncogene-specific TKI, and 2 were offered a 
genotype-specific trial upon subsequent progression. One patient with an ERBB2-mutated 
AC received off-label afatinib (a clinical trial for this genotype had closed to accrual). 
Another patient with a MET exon 14 splicing mutation was offered off-label crizotinib at 
first progression. While not FDA-approved for the latter two indications, these TKIs are 
acknowledged as targeted therapies for consideration as per the National Comprehensive 
Cancer Network (NCCN) guidelines for NSCLC (3).
The results of NGS assays were of lesser therapeutic consequence in the 7 SC carcinomas, 
where all tumors harbored TP53 mutations but lacked the prevalent/principal driver 
oncogenes observed in ACs (1/7 or 14.2% vs. 10/17 or 58.8% in SC vs. AC, respectively; 
p=0.0778). Only 1 case of borderline FGFR1 amplification was identified, but this did not 
lead to a change in clinical decision-making as the clinical trial of an FGFR inhibitor 
(NCT01703481) available at our institution at the time was not applicable for this patient; 
this patient received concurrent chemoradiation as per expert guidelines. Therefore, in none 
of the cases of SC carcinoma were clinical decisions altered by NGS results—a proportion 
that was notably lower than that observed in those patients with AC (0% or 0/7 vs. 47.0% or 
8/17 for SC vs. AC, respectively; p=0.0538). The therapeutic utility of tumor genotyping 
stratified by histology is indicated in Figure 2 and Table 2.
3.4 Alterations in driver oncogenes in lung ACs from never or light smokers
Driver oncogenes - for which TKIs are approved or have some level of clinical evidence (i.e. 
EGFR, ALK, ROS1, RET, ERBB2, MET) - identified by combined SGAs and/or NGS 
(Figure 2) were significantly more frequent in patients with a ≤ 15 pack-year tobacco history 
(18/27, 66.6%) than in those with > 15 pack-years of tobacco use (3/42, 7.1%; p<0.0001). 
KRAS mutations were more frequent in the group with > 15 pack-years of tobacco use 
(17/42 or 40.4% vs. 5/27 or 18.5%, respectively; p=0.0682).
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4. DISCUSSION
The care of advanced NSCLC has evolved dramatically in the last decade, owing to the 
evolution of targeted, biologically pertinent therapies offered on the basis of vetted genomic 
biomarkers. When used in these genotype-specific settings, targeted therapies have afforded 
consistent improvements in progression-free survival and quality of life, as compared to 
conventional cytotoxic agents (4-10). Unsurprisingly, oncology patients and providers in 
academic and community settings alike are increasingly aware of, desire, and are incumbent 
to obtain timely and accurate tumor genomic testing to help guide therapeutic decision-
making (18, 19). It is also now apparent that the genomic landscape of NSCLC extends 
beyond EGFR and ALK alone, with potentially relevant aberrations also found in: KRAS, 
BRAF, ERBB2, RET, ROS1, NTRK1, FGFR 1/2/3/4, PIK3CA, and DDR2, among others (10, 
11).
4.1 Outcomes of NGS use in NSCLC by other groups
The clinical utility of comprehensive genomic analyses of lung ACs has been recently 
highlighted by the Lung Cancer Mutation Consortium (LCMC), which analyzed 10 potential 
genomic drivers from tumor specimens obtained from academic centers nationwide (20). An 
oncogenic driver was found in 64% of tumors; these results were subsequently used to select 
a precision therapy or clinical trial in 28% of cases. Notably, median survival was improved 
for those patients whose tumors harbored an abnormality amenable to a genotype-directed 
therapy (20). The Washington University lung cancer program recently published their 
experience with an internally-developed 23-gene NGS assay (21). A 45% assay failure rate 
was noted; however, NGS afforded actionable information in 46% of successfully assayed 
NSCLCs, and a targeted therapy was instituted in 11% of genotyped tumors (21). Similarly, 
colleagues at Memorial Sloan Kettering used hybrid-capture-based NGS testing 
(FoundationOne) following serial negative SGAs in patients with AC and light/no (≤15 
pack-year) tobacco use (22). 34% of patients were excluded on the basis of tissue exhaustion 
from prior testing. Actionable genomic changes were identified in 39% of patients (using 
targeted therapies on/off study) (22). We are unaware of other peer-reviewed publications 
detailing the clinical application of NGS in day-to-day practice in a multidisciplinary 
NSCLC clinic.
4.2 NGS in EGFR, ALK, KRAS-wild type tumors
In the cohort presented here, NGS was used in greater than one-third of cases and in a 
rationally selected subset with tumors most likely to harbor changes that may render 
genotype-directed therapy of use, i.e.: patients without other common driver mutations 
(EGFR, ALK, and KRAS) and/or those with light/no tobacco use (≤15 pack-years). This 
cohort highlights the application of NGS in routine clinical practice and not in parallel with 
other efforts (i.e. assay development or clinical trial screening) (20-22). Therefore, it serves 
as an instructive platform for assessing how this technology is being adopted, implemented, 
and applied in daily care.
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4.3 Pearls and pitfalls of NGS use
Important limitations of this analysis include: its retrospective nature, the limited sample 
size, utilization of archival tissue, and absence of direct involvement in NGS analysis/
interpretation. Moreover, we currently have no pre-specified algorithm to direct obtaining 
and integrating genomic results into patient care, beyond application of approved targeted 
therapies in selected populations.
NGS was successfully executed in the vast majority of submitted samples (>80%). As 
observed by our group and others, driver oncogenes with known therapeutic potential were 
more readily identified in those with AC vs. SC histology. NGS of ACs impacted real-world 
decision-making in nearly half of cases, enabling genotype-specific therapies. In most ACs 
in which a driver mutation was identified and a relevant clinical trial available/appropriate, 
enrollment was offered. We favor this strategy for integrating genomic data into patient care, 
so as to drive participation in genotype-directed trials and facilitate rational and rigorous 
approval of novel therapies and targeted applications. During our data collection period, our 
center had active protocols for tumors with aberrations in EGFR, ALK, ROS1, MET, KRAS 
and ERBB2.
4.4 NGS use in SC carcinomas
Genomic results (NGS or SGAs) for SC carcinomas did not lead to practice changes in our 
cohort. The number of cases analyzed was small, and additional numbers would have likely 
revealed tumors with PI3KCA, DDR2, and FGFR aberrations; these have been described by 
other groups as potentially targetable in preclinical models (10, 11). However, the absence 
of known bona fide driver oncogenes in the majority of SC carcinomas (10) has made the 
evolution of targeted therapies for this histologic subtype much slower. To date, no TKI is 
approved by regulatory agencies or recommended by the NCCN for SC carcinomas (3). This 
unmet clinical need has led to development of novel biomarker-driven trials. The National 
Clinical Trials Network (NCTN) has recently started the LUNG-Map/S1400 
(NCT02154490) trial to address this need (http://www.lung-map.org/). This is a multi-armed 
randomized phase II/III trial emphasizing matched gene-drug strategies using the 
FoundationOne platform for NGS. If LUNG-Map is successful, then NGS and novel 
targeted drugs may become part of the standard approach to managing SC lung cancers, as 
well.
4.5 Optimizing NGS use in day-to-day practice
It is speculative to consider whether if used as a sole method, NGS may have allowed for 
detection of all clinically-relevant genomic alterations, with a higher success rate, and 
without the time, effort, cost, and tissue exhaustion associated with sequential testing. As 
have others, we note that there was a trend toward more frequent NGS failure rates in 
samples where SGAs preceded. These factors underscore the critical importance of timely 
and effective collaboration between members of the multidisciplinary team to obtain, select, 
and retain optimal specimen(s) for effective testing. Enthusiasm for the routine use of up-
front NGS should be tempered by consideration of the financial, medical, and psychosocial 
costs and cost effectiveness of this approach. This includes consideration of “costs” 
associated with the assay itself, subsequent anti-cancer medication(s), additional tissue 
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acquisition procedures, therapeutic delays pending tissue testing, and inadequately known 
benefits/risks for the patient. Such efforts should occur in parallel with the development and 
application of these genomic platforms. It is an urgent need to establish the optimal use of 
genomic testing (i.e. sequential SGAs versus NGS) in the day-to-day care of NSCLC 
patients.
The evolution of genotype-directed cancer care also has implications for the education of 
medical professionals. A recent publication testifies to this unmet need: in a study of 160 
faculty members at a well-known academic cancer center, higher “genomic confidence” was 
associated with a higher likelihood that a provider would obtain and apply genomic data to 
patient care; 22% of surveyed cancer providers indicated low confidence in their genomic 
knowledge (19). Targeted areas for genomic oncology curricula should include: 
methodologies for genomic assessment (i.e. understanding what methods are specifically 
utilized by commercial/institutional genomic assay vendors); optimal/adequate specimen 
selection; utilization of validated resources for interpretation of results; understanding the 
therapeutic implications—or lack thereof—of a given finding; obtaining informed consent 
for testing from patients; and discussing results of testing with patients—including findings 
of uncertain significance. In recognition of this evolving and increasingly apparent 
educational need, colleagues have already started to take systematic approaches to educate 
trainees in this important domain (23-25).
5. CONCLUSIONS
In summary, we report the patterns of use and implications of NGS testing in an academic 
thoracic oncology clinic. Sequential single gene and targeted NGS assays can identify a 
significant number of confirmed driver events in lung ACs for which targeted therapies are 
either already available or in development. NGS is particularly impactful in never/light 
smokers and in whom first pass SGAs do not identify any targetable abnormalities, as this 
subset is likely to be enriched with oncogenic targets that are of therapeutic relevance. In SC 
lung cancers, however, the impact of NGS in standard practice remains unclear, and 
innovative biomarker-driven trials have commenced to address this unmet need. The growth 
of platforms that permit rapid tumor genotyping has fueled a furtive interest in the 
development and application of personalized approaches in cancer therapeutics. 
Comprehensive first line genotyping of NSCLCs using NGS is therefore an attractive 
extension of these efforts. However, future research into the cost and relative impact/
effectiveness of this approach, as well as improved training of medical professionals in the 
practice of genomic oncology, are warranted to maximize this strategy of care.
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CLINICAL PRACTICE POINTS
- Tumor genotyping using single gene assays for EGFR mutation and ALK 
rearrangementare standard practice in advanced non-small-cell lung cancer;
- Targeted next generation sequencing can identify a significant number of 
therapeutically-relevant driver events in lung adenocarcinoma; particularly in never 
or light smokers;
- The introduction of next generation sequencing/comprehensive molecular profiling 
into day-to-day clinical practice altered therapeutic decision-making and increased 
the number of cases that can benefit from precision oncology;
- Further research into the cost effectiveness and optimal use of next generation 
sequencing and improved provider training in genomic oncology are warranted.
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Figure 1. 
Flow chart of genomic analyses over a 6-month period. A.) Single gene assays: results, 
clinical decisions and trial evaluation. B.) Next generation sequencing (NGS) assays: results, 
clinical decisions and trial evaluation.
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Figure 2. 
Genomic abnormalities stratified by histology and patient smoking status. A.) Genomic 
findings and targeted therapies in adenocarcinomas, as identified by next generation 
sequencing (NGS). B.) Genomic findings and targeted therapies in squamous cell 
carcinomas, as identified by NGS. C.) Genomic findings and targeted therapies in 
adenocarcinomas from never-/light- smokers [≤ 15 pack-years smoking]. D.) Genomic 
findings and targeted therapies in adenocarcinomas from patients with > 15 pack-years 
smoking.
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Table 1
Baseline characteristics of patients and tumors genotyped over a 6-month period.
Age at time of tissue acquisition
Median (range) 67 (34-92)
Women n (%)
Men n (%)
49 (59.7)
33 (40.3)
Race n (%)
 White
 Asian
 Black
 Other
66 (80.5)
8 (9.8)
5 (6.1)
3 (3.6)
Smoking status n (%)
 Current smoker
 Former smoker
 Never smoker
27 (32.9)
41 (50.0)
14 (17.1)
Stage n (%)
 I-III
 IV/recurrent
23 (28.0)
59 (72.0)
Histology n (%)
 Adenocarcinoma
 Squamous cell carcinoma
 NSCLC (NOS)
74 (90.2)
7 (8.5)
1 (1.2)
Type of tissue n (%)
 Surgical specimen
 Small biopsy
 Cytology block from aspirate/fluid
22 (26.8)
17 (20.7)
43 (52.4)
Anatomic site of tissue acquisition n (%)
Bone
 Brain
Extra-thoracic lymph node
Lung
Mediastinal/hilar lymph node
Pleura
 Other
4 (4.9)
3 (3.6)
5 (6.1)
27 (32.9)
24 (29.3)
12 (14.6)
7 (8.5)
NSCLC, non-small-cell lung cancer; NOS, not otherwise specified
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